公开(公告)号：US20220379028A1

公开(公告)日：2022-12-01

申请号：US17818504

申请日：2022-08-09

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  G16H40/63 ,  A61K38/28 ,  A61M31/00

Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

公开(公告)号：US20220293234A1

公开(公告)日：2022-09-15

申请号：US17691829

申请日：2022-03-10

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Eric BENJAMIN ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: G16H20/13 ,  A61M5/172

Abstract: The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.

公开(公告)号：US20220288300A1

公开(公告)日：2022-09-15

申请号：US17330115

申请日：2021-05-25

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY

IPC: A61M5/142 ,  G06Q30/02

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US20220203023A1

公开(公告)日：2022-06-30

申请号：US17514336

申请日：2021-10-29

Applicant: Insulet Corporation

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  David NAZZARO ,  Yibin ZHENG ,  Pauline TANDON

IPC: A61M5/168 ,  A61M5/142

Abstract: A system for automatically delivering medication to a user is disclosed. A sensor worn by the user can collect information regarding the user. A user device, for example, a smartphone, executes a user application that uses the collected information to determine an amount of medication to provide to the user. The user application includes a graphical user interface that allows the user to easily interact with the user application to specify various aspects of the delivery of the medication. The user application controls a wearable drug delivery device to dispense the medication to the user.

公开(公告)号：US20220096746A1

公开(公告)日：2022-03-31

申请号：US17545256

申请日：2021-12-08

Applicant: Insulet Corporation

Inventor： David NAZZARO ,  John D`ARCO ,  Jason O'CONNOR ,  Ian MCLAUGHLIN

IPC: A61M5/168 ,  A61B5/145 ,  A61M5/142 ,  A61M5/172

Abstract: A drug delivery system having a drug delivery device and an associated sensor is provided. The sensor can be associated with a sensing site on user. The drug delivery device can be positioned over the sensor in any rotational position and can be associated with an infusion site on the user. The close positioning of the sensor and the drug delivery device allows data from the sensor to be relayed to the drug delivery device and then on to a remote control device. Further, the drug delivery device can be replaced at the end of its duration of use, which is shorter than the duration of use of the sensor, without disturbing the sensor. Subsequent drug delivery devices can then be used with the sensor while allowing each corresponding infusion site to be changed, thereby providing more efficient operation of the drug delivery system.

公开(公告)号：US20220062546A1

公开(公告)日：2022-03-03

申请号：US17008101

申请日：2020-08-31

Applicant: Insulet Corporation

Inventor： Eric BENJAMIN ,  Jason O'CONNOR ,  Yibin ZHENG ,  Joon Bok LEE ,  Mark BOYNS

IPC: A61M5/172 ,  G16H50/30 ,  G16H40/40 ,  G16H40/67 ,  G16H50/20 ,  G16H50/70 ,  G16H10/60 ,  G16H20/13 ,  G06F9/445

Abstract: The exemplary embodiments allow a user to have more aggressive settings or less aggressive settings for an AID system after demonstrating good blood glucose level control. This allows the settings to be more quickly customized to users that demonstrate good quality blood glucose level control than conventional systems. As these users have demonstrated good quality glucose level control there is less of a need to constrain the settings and provide a high margin of safety. Conversely, users demonstrating poor quality blood glucose level control may have less aggressive settings imposed, representing a higher margin of safety.

公开(公告)号：US20220062542A1

公开(公告)日：2022-03-03

申请号：US17412666

申请日：2021-08-26

Applicant: Insulet Corporation

Inventor： David NAZZARO ,  Jason O'CONNOR ,  Ian MCLAUGHLIN ,  Philip HILLDALE ,  Joon Bok LEE ,  Bret CHRISTENSEN ,  Maureen MCCAFFREY ,  Thomas METZMAKER

IPC: A61M5/168 ,  A61M5/142 ,  A61M5/158 ,  A61M5/172

Abstract: Embodiments of the present disclosure relate to techniques, processes, devices or systems for automating fluid delivery without the use of an external interface device. In one approach, a wearable drug delivery device may include a reservoir configured to store a liquid drug, a pump mechanism coupled to the reservoir and operable to expel the liquid drug from the reservoir, and a mechanical triggering device engageable by a user. The mechanical triggering device is operable to change between a first configuration and a second configuration to control deployment of a needle to deliver the liquid drug into a patient.

公开(公告)号：US20220023536A1

公开(公告)日：2022-01-27

申请号：US17377801

申请日：2021-07-16

Applicant: Insulet Corporation

Inventor： James GRAHAM ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  G16H40/67 ,  G16H20/17 ,  G16H10/60

Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.

公开(公告)号：US20210313037A1

公开(公告)日：2021-10-07

申请号：US16840603

申请日：2020-04-06

Applicant: INSULET CORPORATION

Inventor： Jason O'CONNOR ,  Ian MCLAUGHLIN ,  Daniel ALLIS ,  Paul Frederick BENTE, IV ,  Steven CARDINALI ,  Joon Bok LEE

IPC: G16H20/30 ,  G16H10/60 ,  G16H20/17 ,  G16H40/63 ,  G16H50/50 ,  A61M5/168 ,  G16H30/20

Abstract: A system, techniques, and computer-readable media includes examples that provide an indication of an early exercise detection are described. An example of an early exercise detection application executed by a processor may cause the processor to perform functions and be operable to obtain image data including metadata from a camera of a mobile device during, for example, an unlock procedure of a mobile device. The processor may determine whether the obtained image data includes location or timestamp information in metadata or has image data that may be recognized as exercise-related objects. Based on the determinations, the processor may output an indication of early exercise detection to an artificial pancreas application, which is operable to adjust an amount of insulin to be delivered to a user.

公开(公告)号：US20210244880A1

公开(公告)日：2021-08-12

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Trang LY ,  Yibin ZHENG ,  Connor GULLIFER ,  Kyle GROVER

IPC: A61M5/172 ,  G16H20/17

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.